Cited by 915Lung Cancer Treatments and MutationsLung Cancer Diagnosis and TreatmentLung Cancer Research Studies

The DOI matches its Crossref record; 216 of the 218 references it cites were found in a registry or an index.

American Society of Clinical Oncology Clinical Practice Guideline Update on Chemotherapy for Stage IV Non–Small-Cell Lung Cancer

Open access

Azzoli, Christopher G., Baker, Sherman, Temin, Sarah, Pao, William, Aliff, Timothy, Brahmer, Julie, Johnson, David H., Laskin, Janessa L., Masters, Gregory, Milton, Daniel, Nordquist, Luke, Pfister, David G., Piantadosi, Steven, Schiller, Joan H., Smith, Reily, Smith, Thomas J., Strawn, John R., Trent, David, Giaccone, Giuseppe·2009·Journal of Clinical Oncology

DOI 10.1200/jco.2009.23.5622PMC PMC2793036

Open this paper in CoChat — free account

Abstract

The purpose of this article is to provide updated recommendations for the treatment of patients with stage IV non-small-cell lung cancer. A literature search identified relevant randomized trials published since 2002. The scope of the guideline was narrowed to chemotherapy and biologic therapy. An Update Committee reviewed the literature and made updated recommendations. One hundred sixty-two publications met the inclusion criteria. Recommendations were based on treatment strategies that improve overall survival. Treatments that improve only progression-free survival prompted scrutiny of toxicity and quality of life. For first-line therapy in patients with performance status of 0 or 1, a platinum-based two-drug combination of cytotoxic drugs is recommended. Nonplatinum cytotoxic doublets are acceptable for patients with contraindications to platinum therapy. For patients with performance status of 2, a single cytotoxic drug is sufficient. Stop first-line cytotoxic chemotherapy at disease progression or after four cycles in patients who are not responding to treatment. Stop two-drug cytotoxic chemotherapy at six cycles even in patients who are responding to therapy. The first-line use of gefitinib may be recommended for patients with known epidermal growth factor receptor (EGFR) mutation; for negative or unknown EGFR mutation status, cytotoxic chemotherapy is preferred. Bevacizumab is recommended with carboplatin-paclitaxel, except for patients with certain clinical characteristics. Cetuximab is recommended with cisplatin-vinorelbine for patients with EGFR-positive tumors by immunohistochemistry. Docetaxel, erlotinib, gefitinib, or pemetrexed is recommended as second-line therapy. Erlotinib is recommended as third-line therapy for patients who have not received prior erlotinib or gefitinib. Data are insufficient to recommend the routine third-line use of cytotoxic drugs. Data are insufficient to recommend routine use of molecular markers to select chemotherapy.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1200/jco.2009.23.5622

Cites

216 of 216 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Toxicity and response criteria of the Eastern Cooperative Oncology Group
Oken, M. M., Creech, R. H., Tormey, D. C., Horton, J., Davis, T. E., Mcfadden, E. T., & Carbone, P. P. (1982) · American Journal of Clinical Oncology · doi:10.1097/00000421-198212000-00014 · Cited by 11,686
Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to Gefitinib
Lynch, T. J., Bell, D. W., Sordella, R., Gurubhagavatula, S., Okimoto, R. A., Brannigan, B. W., Harris, P. L., Haserlat, S. M., Supko, J. G., Haluska, F. G., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040938 · Cited by 11,486
EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy
Paez, J. G., Jänne, P. A., Lee, J. C., Tracy, S., Greulich, H., Gabriel, S., Herman, P., Kaye, F. J., Lindeman, N., Boggon, T. J., et al. (2004) · Science · doi:10.1126/science.1099314 · Cited by 9,368
Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
Mok, T. S., Wu, Y.-L., Thongprasert, S., Yang, C.-H., Chu, D.-T., Saijo, N., Sunpaweravong, P., Han, B., Margono, B., Ichinose, Y., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0810699 · Cited by 8,261
Paclitaxel–Carboplatin Alone or with Bevacizumab for Non–Small-Cell Lung Cancer
Sandler, A., Gray, R., Perry, M. C., Brahmer, J., Schiller, J. H., Dowlati, A., Lilenbaum, R., & Johnson, D. H. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa061884 · Cited by 5,761
Self-citation
Erlotinib in Previously Treated Non–Small-Cell Lung Cancer
Shepherd, F. A., Rodrigues Pereira, J., Ciuleanu, T., Tan, E. H., Hirsh, V., Thongprasert, S., Campos, D., Maoleekoonpiroj, S., Smylie, M., Martins, R., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050753 · Cited by 5,419
ras oncogenes in human cancer: a review.
Bos, J. L. (1989) · PubMed · Cited by 5,061
EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinib
Pao, W., Miller, V., Zakowski, M., Doherty, J., Politi, K., Sarkaria, I., Singh, B., Heelan, R., Rusch, V., Fulton, L., et al. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0405220101 · Cited by 4,338
Self-citation
COMPARISON OF FOUR CHEMOTHERAPY REGIMENS FOR ADVANCED NON-SMALL-CELL LUNG CANCER
Chiller, J. O. H. S., Arrington, D. A. H., Elani, C. H. P. B., Anger, C., Andler, A. L. S., Rook, J. A. K., Hu, J., & Ohnson, D. A. H. J. (2002) · Cited by 3,730
The IASLC Lung Cancer Staging Project: Proposals for the Revision of the TNM Stage Groupings in the Forthcoming (Seventh) Edition of the TNM Classification of Malignant Tumours
Goldstraw, P., Crowley, J., Chansky, K., Giroux, D. J., Groome, P. A., Rami-Porta, R., Postmus, P. E., Rusch, V., & Sobin, L. (2007) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e31812f3c1a · Cited by 3,655

Show all 218 references

Research works printed but not linked: 7

10.1200/jco.2002.20.5.1335 · DOI
Lynch TJ, Presented at the 12th World Conference on Lung Cancer
Lord RV, 2002, Clin Cancer Res, 8, 2286
Mihaylova Z, 2007, J BUON, 12, 105
Langer CJ, 2004, Oncology, 18, 17
Brose MS, 2002, Cancer Res, 62, 6997
Suzuki Y, 1990, Oncogene, 5, 1037

Sorted by citations

Items 701–800 of 911

Changes in T-lymphocytes in lung cancer patients after hyperthermic intraperitoneal chemotherapy or radiotherapy
Yan, L., Wu, M., Ba, N., Shi, G., Wang, L.-R., & Zhang, H. (2016) · Genetics and Molecular Research · doi:10.4238/gmr.15027865 · Cited by 4
k-RAS mutations in non-small cell lung cancer patients treated with TKIs among smokers and non-smokers: a meta-analysis
Jiang, A.-G., & Lu, H. (2016) · Współczesna Onkologia · doi:10.5114/wo.2016.60068 · Cited by 6
Comparison of Symptom Score and Bronchoscopy-Based Assessment With Conventional Computed Tomography–Based Assessment of Response to Chemotherapy in Lung Cancer
Yenge, L. B., Behera, D., Garg, M. K., Aggarwal, A. N., & Singh, N. (2017) · Journal of Global Oncology · doi:10.1200/jgo.2016.006593 · Cited by 4
Switch maintenance therapy with docetaxel and bevacizumab after induction therapy with cisplatin, pemetrexed, and bevacizumab in advanced non-squamous non-small cell lung cancer: a phase II study
Nishimoto, K., Karayama, M., Inui, N., Yasui, H., Hozumi, H., Suzuki, Y., Furuhashi, K., Fujisawa, T., Enomoto, N., Nakamura, Y., et al. (2018) · Medical Oncology · doi:10.1007/s12032-018-1172-x · Cited by 4
Comparison of efficacy and safety of single-agent and doublet chemotherapy in advanced non-small cell lung cancer in the elderly: A meta-analysis.
Guetz, G. D., Uzzan, B., Nicolas, P., Chouahnia, K., Perret, G. Y., Sebbane, G., & Morère, J. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.28.15_suppl.7625 · Cited by 4
N6-methyladenosine modification of MRP7 mRNA modulates its expression and paclitaxel sensitivity in lung cancer-derived A549 cells
Inamoto, T., Nakano, M., Fukami, T., & Nakajima, M. (2026) · Drug Metabolism and Pharmacokinetics · doi:10.1016/j.dmpk.2026.101519 · Cited by 3
Phase I dose escalation study of amrubicin plus paclitaxel in previously treated advanced non-small cell lung cancer
Kaira, K., Sunaga, N., Imai, H., Kamide, Y., Koga, Y., Ono, A., Kuwako, T., Masuda, T., Hisada, T., Ishizuka, T., et al. (2015) · International Journal of Clinical Oncology · doi:10.1007/s10147-015-0883-7 · Cited by 3
Place des traitements ciblés dans la prise en charge des cancers broncho-pulmonaires
Staudacher, L., Teixeira, L., Kempf, E., Rousseau-Bussac, G., Jouveshomme, S., Cohen, R., Beuzelin, C., Jagot, J.-L., Salmerón, S., & Trédaniel, J. (2012) · Pathologie Biologie · doi:10.1016/j.patbio.2012.05.011 · Cited by 3
Analysis of continuous first-line treatment with docetaxel and carboplatin for advanced non-small cell lung cancer
Aoki, T., Ebihara, A., Yogo, Y., Suemasu, K., & Sakamaki, F. (2014) · Oncology Letters · doi:10.3892/ol.2014.1973 · Cited by 3
A randomised phase II trial of two sequential schedules of docetaxel and cisplatin followed by gemcitabine in patients with advanced non-small-cell lung cancer
Grossi, F., de Marinis, F., Gebbia, V., Riccardi, F., Caffo, O., Gamucci, T., Ferraù, F., Nardi, M. J., Moscetti, L. I., Boni, L., et al. (2011) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-011-1710-0 · Cited by 3
Efectividad y toxicidad de erlotinib en la farmacoterapia del cáncer de pulmón no microcítico
Romero‐Ventosa, E. Y., Molina, A. M., Pedrido, R. M., Rivero, N. L., Constenla-Caramés, L., & Arias-Santos, I. (2011) · Farmacia Hospitalaria · doi:10.1016/j.farma.2010.12.005 · Cited by 3
Gemeinsam mit dem Patienten klug entscheiden
Fölsch, U. R., & Hasenfuss, G. P. (2016) · Der Internist · doi:10.1007/s00108-016-0069-z · Cited by 3
Cetuximab-Associated Crescentic Diffuse Proliferative Glomerulonephritis
Manthri, S., Bandaru, S., Chang, A., & Hudali, T. H. (2017) · Case Reports in Nephrology · doi:10.1155/2017/7964015 · Cited by 3
Anemia in oncology
Sushinskaya, T. V., Li, E.-S., & Stuklov, N. (2021) · P A Herzen Journal of Oncology · doi:10.17116/onkolog20211001164 · Cited by 3
Malignant breast lesions detection in histopathological images based on the combination of bioinspired texture descriptors and deep features
Luz, D. D. S., Bisneto, T. R. V., Lima, T. J. B., Mathew, M. J., & Araújo, F. H. D. (2023) · Computer Methods in Biomechanics and Biomedical Engineering Imaging & Visualization · doi:10.1080/21681163.2023.2198037 · Cited by 3
Systematic review and meta-analysis of third-line salvage therapy for the treatment of advanced non-small-cell lung cancer: A meta-analysis of randomized controlled trials
Zhang, N., Guo, N., Tian, L., & Miao, Z. (2018) · Oncotarget · doi:10.18632/oncotarget.24967 · Cited by 3
A Rare Case of Syndrome of Inappropriate Anti-diuretic Hormone in Non-small Cell Lung Cancer Presenting as Superior Vena Cava Syndrome
Ishihara, R., Stoos, C. T., Jagadesh, S. K., & Nguyen, C. (2019) · Cureus · doi:10.7759/cureus.4861 · Cited by 3
Safety and efficacy of single‐agent docetaxel ( T axotere) administered weekly in non‐small cell lung carcinoma patients in K orea: An observational study
Lim, S. M., Park, B. B., Park, K., Kim, H.-K., Lee, J. S., Bae, S. H., Lee, S., Kang, J., Park, S., Lee, G., et al. (2015) · Thoracic Cancer · doi:10.1111/1759-7714.12315 · Cited by 3
Napsin A expression in small cell carcinoma of the lung: a cytologic study with review of differentials
HooKim, K., Kavuri, S., Lauer, S. R., Cohen, C., & Reid, M. D. (2013) · Journal of the American Society of Cytopathology · doi:10.1016/j.jasc.2013.11.005 · Cited by 3
Immunotherapy for non-small-cell lung cancer: current approaches
Quoix, É., & Limacher, J. M. (2014) · Current Respiratory Care Reports · doi:10.1007/s13665-014-0072-6 · Cited by 3
Frequency of Epidermal Growth Factor Mutation Status and Its Effect on Outcome of Patients with Adenocarcinoma of the Lung
Shafik, H. E., Al-Shemarri, S. H., Al-Enezi, F., Ashour, M., Khalaf, E., & Al-Khodary, A. I. (2014) · Journal of Cancer Therapy · doi:10.4236/jct.2014.511106 · Cited by 3
The Presence of EGFR Mutations Predicts the Response in Chinese Non-Small Cell Lung Cancer Patients Treated with Erlotinib
Li, R., Zheng, L., Fang, M., & Yu, S. (2014) · The International Journal of Biological Markers · doi:10.5301/jbm.5000059 · Cited by 3
Anticancer treatment for advanced non-small cell lung cancer
Jp, S. (2011) · Breathe · doi:10.1183/20734735.005011 · Cited by 4
Doublets versus single-agent therapy as first-line therapy for elderly patients with advanced non-small cell lung cancer? A systematic review of randomised controlled trials
Chong-an, X., Chang, Z.-Y., Wang, X.-L., & Qi, H.-Y. (2013) · International Journal of Clinical Practice · doi:10.1111/ijcp.12167 · Cited by 3
Long Survival of a Small-Cell Lung Cancer Patient Who Received Maintenance Chemotherapy with Irinotecan
Yagi, Y., Kim, Y. H., Tajima, N., Baba, K., Aihara, K., Soo, H. H., Yamaoka, S., & Mishima, M. (2013) · Case Reports in Oncology · doi:10.1159/000356826 · Cited by 3
The EGFR and KRAS Mutation Status and Correlations with the Prevalence of Bone Metastases - The Results of Three Year Retrospective Analysis
Balikó, Z. (2014) · Journal of Carcinogenesis & Mutagenesis · doi:10.4172/2157-2518.1000184 · Cited by 2
Molecular Targeted Therapy of Lung Cancer
Đačić, S. (2012) · Molecular pathology library · doi:10.1007/978-1-4614-3197-8_10 · Cited by 3
Molecular Testing in Lung Cancer
Shiau, C. J., & Tsao, M. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-800886-7.00023-6 · Cited by 3
Dynamic change of fatigue of pemetrexed maintenance treatment in the JMEN trial
Zhang, L., Belani, C. P., Zhang, P.-H., Wang, X., Yang, L., Orlando, M., & Wu, Y.-L. L. C. (2017) · Lung Cancer · doi:10.1016/j.lungcan.2017.11.026 · Cited by 3
Switch maintenance therapy with S-1 after induction therapy with carboplatin and nanoparticle albumin-bound paclitaxel in advanced lung squamous cell carcinoma
Akiyama, N., Karayama, M., Inui, N., Yasui, H., Hozumi, H., Suzuki, Y., Furuhashi, K., Fujisawa, T., Enomoto, N., Nakamura, Y., et al. (2019) · Investigational New Drugs · doi:10.1007/s10637-019-00747-x · Cited by 3
The Effect of Next-Generation TKI in Non-Small Cell Lung Cancer after Failure of First-Line Treatment: a Meta-Analysis
Zhang, L., Ren, H., Wu, Q., Wu, Y.-J., & Song, X. (2019) · Pathology & Oncology Research · doi:10.1007/s12253-019-00669-2 · Cited by 3
What is the role of maintenance therapy in the treatment of non-small cell lung cancer?
Jiang, Y., Owonikoko, T. K., Ramalingam, S. S., Khuri, F. R., & Belani, C. P. (2010) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758834010368045 · Cited by 3
Osimertinib treatment response in a patient with lung adenocarcinoma harboring two rare EGFR mutations: A case report
Luo, Y., Lin, L., Shufeng, C., Liu, C., Li, Z., & Liu, K. (2024) · Oncology Letters · doi:10.3892/ol.2024.14634 · Cited by 2
Data set for the reporting of lung cancer: recommendations from the International Collaboration on Cancer Reporting ( ICCR )
Cooper, W. A., Webster, F., Butnor, K. J., Calabrese, F., Chou, T., Hwang, D. M., Kern, I., Popat, S., Sholl, L. M., Yatabe, Y., et al. (2024) · Histopathology · doi:10.1111/his.15313 · Cited by 3
Comparing Quality of Life and Psychological Changes in Benign and Malignant Lung Resections
Nicola, A. C., Mavrea, A., Poroșnicu, T. M., Oancea, C. I., Marc, M. S., & Barata, P. I. (2024) · Healthcare · doi:10.3390/healthcare13010006 · Cited by 2
Case report: Immune checkpoint inhibitor-induced fulminant diabetic ketoacidosis: a case-based review and considerations for immunotherapy discontinuation
Zhao, S., Liu, X., Tan, P., Mu, Y., Tan, S., & Hou, A. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1747371 · Cited by 2
Low Dose Fractionated Cisplatin Plus Gemcitabine for Elderly Patients with Advanced Non Small Cell Lung Cancer: A Retrospective Analysis
Pezzuolo, D., Pennucci, M. C., Mambrini, A., Pacetti, P., Orlandi, M., Tartarini, R., Freo, A. D., & Cantore, M. (2010) · Journal of Chemotherapy · doi:10.1179/joc.2010.22.4.275 · Cited by 2
Molecular Targets in the Treatment of Non—Small-Cell Lung Cancer: Is There Hope on the Horizon?
Carter, C. A., Nations, J. A., & Lazarus, A. A. (2014) · Postgraduate Medicine · doi:10.3810/pgm.2014.11.2842 · Cited by 2
Toxicity Profile and Adherence to the Pharmacotherapeutic Regimen of Gemcitabine–carboplatin in Non-small Cell Lung Cancer
Herrero, D. G., Marí, A. A., Sanjuán, M. M., Ferrer, M. L. B., & Torres, N. V. J. (2011) · Farmacia Hospitalaria (English Edition) · doi:10.1016/j.farmae.2010.09.001 · Cited by 2
Neurotoxicity of Cisplatin as Monotherapy or Combined Chemotherapy in Cancer Treatment
Volpini, A. N., Marques, I. J. D. S., & Cavalcanti, I. D. L. (2022) · Clinical Cancer Drugs · doi:10.2174/2212697x09666220629161535 · Cited by 2
Salvage chemotherapy in patients with nonsmall cell lung cancer after prior immunotherapy: a retrospective, real-life experience study
Diker, Ö., & Olgun, P. (2022) · Anti-Cancer Drugs · doi:10.1097/cad.0000000000001330 · Cited by 2
Bévacizumab et cancer bronchique : population cible en pratique quotidienne
Lagnien-Gaume, V., Jehl, J., Manzoni, P., Jacoulet, P., Gainet-Brun, M., Metzger, F., Pernet, D., Polio, J. C., Pugin, J., Corgne, J., et al. (2011) · Revue des Maladies Respiratoires · doi:10.1016/j.rmr.2010.05.016 · Cited by 2
First-line chemotherapy with planned sequential administration of cisplatin/gemcitabine followed by docetaxel in elderly ‘unfrail’ patients with advanced non-small-cell lung cancer: a multicenter phase II study
Tibaldi, C., Camerini, A., D’Incecco, A., Vasile, E., Fabbri, A., AMOROSO, D., & Cappuzzo, F. (2012) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-012-1280-5 · Cited by 2
Economic evaluation of pemetrexed versus erlotinib as second-line treatment of patients with advanced/metastatic non-small cell lung cancer in Greece: a cost minimization analysis
Fragoulakis, V., Pallis, A. G., Kateilidou, Maniadakis, N. M., & Georgoulias, V. (2012) · Lung Cancer Targets and Therapy · doi:10.2147/lctt.s33608 · Cited by 2
Defining the Issues in the Treatment of Elderly Patients With Advanced Non-Small-Cell Lung Cancer
Gajra, A. (2015) · Lung Cancer Management · doi:10.2217/lmt.14.42 · Cited by 2
Prospective phase II trial of a combination of gemcitabine and UFT as first-line treatment in elderly patients with advanced non-small cell lung cancer
Baek, J. H., Kim, H., Ahn, J., Jegal, Y., Seo, K. W., Won, S. H., Park, C. R., Jung, J. P., Kim, J. W., Lee, Y. J., et al. (2011) · Lung Cancer · doi:10.1016/j.lungcan.2011.11.021 · Cited by 2
Maladie oligométastatique dans le cancer bronchique non à petites cellules
Quoix, É., Milleron, B. J., & Beau‐Faller, M. (2014) · Revue des Maladies Respiratoires Actualités · doi:10.1016/s1877-1203(14)70605-6 · Cited by 2
Report of clinical studies on chronochemotherapy for advanced non-small cell lung cancer in China
Ji, M. Q., Li, X., Zhang, H., Ning, Z., Zhang, X., Zhao, W., Zhu, L.-N., Li, J., & Wu, C. (2014) · Tumor Biology · doi:10.1007/s13277-014-2539-z · Cited by 2
Epidermal Growth Factor Receptor Mutations as a Prognostic Factor in Korean Patients with Advanced Lung Adenocarcinoma Who Had Not Been Treated with Received Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors
Kim, S. T., Choi, Y. J., Park, K. H., Oh, S. C., Seo, J. H., Shin, S. W., Kim, J. S., & Kim, Y. H. (2011) · Chemotherapy · doi:10.1159/000321490 · Cited by 2
Personalized Therapy in Lung Cancer: Focused on Molecular Targeted Therapy
Lee, S. Y., & Park, J. Y. (2011) · Journal of Lung Cancer · doi:10.6058/jlc.2011.10.1.1 · Cited by 2
Efficacy of third‐generation chemotherapeutic agents combined with cisplatin or carboplatin in 3100 C hinese patients with advanced non‐small‐cell lung cancer
Li, B., Ren, S., Wang, Y., Zhou, C., & Schmid‐Bindert, G. (2012) · Thoracic Cancer · doi:10.1111/j.1759-7714.2012.00173.x · Cited by 2
A retrospective analysis comparing the safety and efficacy of chemotherapy in elderly and non‐elderly non‐small‐cell lung cancer patients
Tsubata, Y., Honda, T., Okimoto, T., Miura, K., Karino, F., Iwamoto, S., Suzuki, T., Hamaguchi, S., Kanda, H., Sutani, A., et al. (2012) · Geriatrics and gerontology international/Geriatrics & gerontology international · doi:10.1111/j.1447-0594.2011.00803.x · Cited by 2
Critical Appraisal of Gefitinib in the Treatment of Non-Small Cell Lung Cancer
Luo, Y., Lee, Y., Whang‐Peng, J., & Chen, Y. (2015) · DOAJ (DOAJ: Directory of Open Access Journals) · doi:10.6323/jcrp.2015.2.3.01 · Cited by 2
Effects of Antacids on Clinical Efficacy of Gefitinib in Patients with Non-Small Cell Lung Cancer
Tanaka, K., Hishinuma, S., Mita, M., Fukaya, Y., Sagawa, K., Kanemura, T., & Shoji, M. (2010) · Iryo Yakugaku (Japanese Journal of Pharmaceutical Health Care and Sciences) · doi:10.5649/jjphcs.36.832 · Cited by 2
Clinical and biological significance of erlotinib therapy after pemetrexed in non-small cell lung cancer with wild-type EGFR
KOYAMA, N., & Suzuki, M. (2015) · Neoplasma · doi:10.4149/neo_2015_121 · Cited by 2
Applicability of the Japanese equation for estimating glomerular filtration rate in patients with advanced-stage thoracic cancer
Kikuchi, T., Akamatsu, H., Mori, K. P., Tanaka, A., Kanai, K., Hayata, A., Tokudome, N., Akamatsu, K., Koh, Y., Nakanishi, M., et al. (2016) · Respiratory Investigation · doi:10.1016/j.resinv.2016.05.007 · Cited by 2
Expression of cross-tolerance to a wide range of conditions in a human lung cancer cell line after adaptation to nitric oxide
Deliu, Z., Tamas, T., Chowdhury, J., Aqil, M., Bassiony, M., & Radosevich, J. A. (2017) · Tumor Biology · doi:10.1177/1010428317723778 · Cited by 2
Evaluating Various Lung Cancer Nodule Detection Techniques—A Comparative Study
Usman, G., Fahiem, M. A., Farhan, S., & Tauseef, H. (2017) · Journal of Testing and Evaluation · doi:10.1520/jte20160410 · Cited by 2
CA916798 gene expression is associated with multidrug resistance and predicts progression‑free survival in patients with lung cancer
Duan, H., Yang, Z., Liang, L., & Zhou, X. (2019) · Oncology Letters · doi:10.3892/ol.2019.10436 · Cited by 2
[Detection of Serum Peptides in Patients with Lung Squamous Cell Carcinoma by MALDI-TOF-MS and Analysis of Their Correlation with Chemotherapy Efficacy].
Zhao, G., Xu, B., Li, X., Tang, C., Qin, H., Wang, H., Yang, S., Wang, W., Gao, H., He, K., et al. (2017) · Europe PMC (PubMed Central) · doi:10.3779/j.issn.1009-3419.2017.05.04 · Cited by 2
How I Treat Non–Small Cell Lung Cancer Refractory to Immunotherapy
Wong, S. K., & Horn, L. (2020) · The Cancer Journal · doi:10.1097/ppo.0000000000000482 · Cited by 2
Molecular Testing in Lung Cancer
Mascaux, C., Tsao, M., & Hirsch, F. R. (2018) · Elsevier eBooks · doi:10.1016/b978-0-323-52357-8.00018-4 · Cited by 2
Using Similarity Metrics on Real World Data and Patient Treatment Pathways to Recommend the Next Treatment.
Haas, K., Morton, S., Gupta, S., & Mahoui, M. (2019) · PubMed Central · Cited by 2
Moving Towards Personalized Medicine
Poungvarin, N. (2020) · DOAJ (DOAJ: Directory of Open Access Journals) · Cited by 2
Cancer of the Lung
Lu, C. S., Morgensztern, D., Chiang, A. C., Onn, A., Sepesi, B., Vaporciyan, A. A., Chang, J. Y., Komaki, R. K., Wistuba, I. I., & Herbst, R. S. (2017) · Holland‐Frei Cancer Medicine · doi:10.1002/9781119000822.hfcm085 · Cited by 2
Cisplatin versus carboplatin in association with third-generation drugs for advanced non-small cell lung cancer
Castria, T. B. D., da Silva, E. M., de Góis, A. F. T., & Riera, R. (2011) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd009256 · Cited by 2
Establishment, culture and characterization of gemcitabine hydrochloride‐resistant human non‐small cell lung carcinoma cell line derived cancer stem cells
Cevizlidere, B. D., Uysal, O. K., Avcı, H., Güneş, S., Sevimli, T. S., DİNÇER, M., Ekenel, E. Q., Kara, S. G., Soykan, M. N., & Sarıboyacı, A. E. (2024) · Cell Biochemistry and Function · doi:10.1002/cbf.4079 · Cited by 1
Efficacy and Safety of Bintrafusp Alfa, a Bifunctional Fusion Protein Targeting Transforming Growth Factor-β and Programmed Death-Ligand 1, Plus Chemotherapy in Patients With Stage IV NSCLC
Rolfo, C. D., Greillier, L., Veillon, R., Badin, F. B., Ghiringhelli, F., Isambert, N., Paulus, A., Chaudhary, S. P., Vugmeyster, Y., Sato, M., et al. (2024) · JTO Clinical and Research Reports · doi:10.1016/j.jtocrr.2024.100748 · Cited by 1
Neoadjuvant Chemoimmunotherapy
Yavuz, G., & Spicer, J. D. (2025) · Thoracic surgery clinics/Thorac. surg. clin. · doi:10.1016/j.thorsurg.2025.09.008 · Cited by 1
Role of [18F]fluorodeoxyglucose positron emission tomography-computed tomography metabolic radiomics in predicting response to chemotherapy in patients with non-small cell lung cancer
Prasanth, P. N., Ravina, M., Ganga, R. T., Raju, S., Kumar, A., Kote, R., Reddy, M., Naik, V. B., Krishnan, S., & Shukla, A. K. (2026) · Nuclear Medicine Communications · doi:10.1097/mnm.0000000000002127 · Cited by 1
Pharmacotherapy Update: Vinorelbine in the Treatment of non-small-cell Lung cancer
Trédaniel, J., Staudacher, L., Teixeira, L., Sebbagh, S., Bucquet, S., & Hennequin, C. (2010) · Clinical Medicine Insights Therapeutics · doi:10.4137/cmt.s4510 · Cited by 1
Tolerability and Outcomes of First-Line Pemetrexed-Cisplatin Followed by Gefitinib Maintenance Therapy Versus Gefitinib Monotherapy in Korean Patients with Advanced Nonsquamous Non-small Cell Lung Cancer: A Post Hoc Descriptive Subgroup Analysis of a Randomized, Phase 3 Trial
Kang, J. H., Ahn, M., Kim, D., Cho, E. K., Kim, J.-H., Shin, S. W., Wang, X., Kim, J. S., Orlando, M., & Park, K. (2015) · Cancer Research and Treatment · doi:10.4143/crt.2015.135 · Cited by 1
Phase I study of docetaxel plus S-1 combination chemotherapy for recurrent non-small cell lung cancer
Fujitaka, K., Hattori, N., SENOO, T., Iwamoto, H., Ohshimo, S., Kanehara, M., Ishikawa, N., Haruta, Y., Murai, H., & Kohno, N. (2010) · Oncology Letters · doi:10.3892/ol.2010.218 · Cited by 1
Defining standard of care for performance status 2—don't rush
Gridelli, C. (2013) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2013.134 · Cited by 1
La stratégie de maintenance en première ligne de traitement dans les cancers bronchiques non à petites cellules avancés
Pérol, M., Odier, L., & Arpin, D. (2010) · Revue des Maladies Respiratoires Actualités · doi:10.1016/s1877-1203(10)70078-1 · Cited by 1
Pemetrexed in Non-Small-Cell Lung Cancer
Dediu, M., Alexandru, A., & Bratu, F. (2014) · Lung Cancer Management · doi:10.2217/lmt.14.16 · Cited by 1
S-1 Combined with Bi-Weekly Docetaxel for Non-Small Cell Lung Cancer Previously Treated with Platinum-Based Chemotherapy: A Phase II Study of North Japan Lung Cancer Group (NJLCG0701)
Ishimoto, O., Sakakibara, T., Maemondo, M., Inoue, A., Matsubara, N., Morikawa, N., Okudera, K., Usui, K., Suzuki, T., Nukiwa, T., et al. (2012) · Cancer and Clinical Oncology · doi:10.5539/cco.v1n1p108 · Cited by 1
The Effectiveness of Maintenance Pharmacotherapies for Non-Small Cell Lung Cancer
Ahn, M., Sun, J., Ahn, J. S., & Park, K. (2012) · Clinical Medicine Insights Oncology · doi:10.4137/cmo.s8001 · Cited by 1
Diagnosis and management of the solitary pulmonary nodule
Weir, G., Kos, S., Burrill, J., Salat, P., Ho, S., & Liu, D. M. (2011) · BMJ · doi:10.1136/bmj.d4866 · Cited by 1
Maintenance therapy in NSCLC
Brodowicz, T. (2012) · memo - Magazine of European Medical Oncology · doi:10.1007/s12254-012-0062-8 · Cited by 1
Perfil de toxicidad y adherencia del esquema farmacoterapéutico gemcitabina-carboplatino en cáncer de pulmón no microcítico
Herrero, D. G., Marí, A. A., Merino‐Sanjuán, M., Ferrer, M. L. B., & Torres, N. V. J. (2011) · Farmacia Hospitalaria · doi:10.1016/j.farma.2010.09.006 · Cited by 1
Prognostic Evaluation and Choice of Second-Line Treatment for Patients with Advanced Non-Small-Cell Lung Cancer
Maïo, M. D., Morabito, A., Daniele, G., Giordano, P., Piccirillo, M. C., Costanzo, R., Sandomenico, C., Montanino, A., Gridelli, C., Rocco, G., et al. (2012) · Lung Cancer Management · doi:10.2217/lmt.12.4 · Cited by 1
Paradigmaváltás a tüdőrákok nem sebészi mintavételében
Strausz, J., & Tı́már, J. (2010) · Magyar Onkológia · doi:10.1556/monkol.54.2010.4.19 · Cited by 1
EGFR TKIs as maintenance therapy in NSCLC: Finding the old in the new INFORMation.
Landi, L. M., & Cappuzzo, F. (2012) · Europe PMC (PubMed Central) · doi:10.3978/j.issn.2218-6751.2012.06.05 · Cited by 1
Management of elderly patients.
Vergnenégre, A., Corre, R., Léna, H., & Caer, H. L. (2013) · Europe PMC (PubMed Central) · doi:10.3978/j.issn.2218-6751.2013.02.04 · Cited by 1
INFORM; C-TONG 0805: A multicenter, double blind randomized phase III trial of maintenance gefitinib compared to placebo in advanced non-small cell lung cancer.
Stinchcombe, T. E. (2012) · Europe PMC (PubMed Central) · doi:10.3978/j.issn.2218-6751.2012.06.03 · Cited by 1
Circulating Endothelial Cells for Evaluation of Tumor Response in Non-Small Cell lung cancer patients receiving first-line chemotherapy
Najjar, F., Al-Massarani, G., Banat, I., & Alammar, M. (2015) · The International Journal of Biological Markers · doi:10.5301/jbm.5000154 · Cited by 1
Bevacizumab en association à une première ligne de chimiothérapie chez des patients atteints d’un cancer bronchique non à petites cellules, non épidermoïde, à un stade avancé ou en rechute : résultats de l’étude non interventionnelle EOLE
CHOUAID, C., Falchero, L., Schött, R., Bonnetain, F., Taguieva-Pioger, N., & Bennouna, J. (2016) · Revue des Maladies Respiratoires · doi:10.1016/j.rmr.2016.05.003 · Cited by 1
Current Status and Future Implications
Stinchcombe, T. E., & Socinski, M. A. (2011) · Cited by 1
Evaluation of the Synergism Mechanism of Tamoxifen and Docetaxel by Nanoparticles
Zhu, Z., Pan, H., Li, Y., & Pan, W. (2019) · Anti-Cancer Agents in Medicinal Chemistry · doi:10.2174/1871520619666190702120829 · Cited by 1
Role of Erlotinib in Influencing the Quality of Life of Cancer Patients
Purohit, D., & Pandey, P. (2020) · Clinical Cancer Drugs · doi:10.2174/2212697x07999200820162006 · Cited by 1
The Role of Pharmaceutical Innovation in Clinical Practice Guidelines for Chronic Diseases
Roach, M., Land, N., Hernandez, J., Rau, R., Chou, J. W., Hickson, S. S., Rollmann, D., & Maclean, J. R. (2024) · International Journal of Clinical Practice · doi:10.1155/2024/5877687 · Cited by 1
[Afatinib Treatment for Advanced Mixed Non-small Cell Lung Cancer with CRISPLD2-NRG1 Fusion: A Case Report and Literature Review].
Chen, C., Yu, Y., & Huang, M. (2024) · PubMed Central · doi:10.3779/j.issn.1009-3419.2024.102.19 · Cited by 1
The role of maintenance pemetrexed in the treatment of non-small-cell lung cancer
Rafii, S. (2010) · Lung Cancer Targets and Therapy · doi:10.2147/lctt.s11542 · Cited by 1
Advances in Lung Cancer and Treatment Research
Wang, X., & Han, B. (2013) · Journal of Cancer Therapy · doi:10.4236/jct.2013.48a006 · Cited by 1
Lung Cancer in Older Adults
Frith, A. E., & Baggstrom, M. Q. (2014) · Current Geriatrics Reports · doi:10.1007/s13670-014-0092-7 · Cited by 1
Advanced Lung Cancer—Reaching a Survival Ceiling with Chemotherapy, the Nibs, and the Mabs
Lencioni, R. A., Chen, J., Downie, G., & Keltner, L. (2011) · Journal of Cancer Therapy · doi:10.4236/jct.2011.22018 · Cited by 1
Chemotherapy for Elderly Patients with Lung Cancer
Okamoto, H. (2015) · Haigan · doi:10.2482/haigan.55.889 · Cited by 1
Assess Nurses’ Performance Regarding Care of Patient with Implanted Port Undergoing Chemotherapy
Hassanien, S. M. E. M., Mohamed, E. T., & Marzouk, S. F. (2019) · Egyptian Journal of Health Care · doi:10.21608/ejhc.2019.36803 · Cited by 1
RETRACTED: Clinical Research on Systemic Chemotherapy Combined With Bronchoscopic Seed Implantation in the Treatment of Advanced Lung Cancer
Xu, F., Yang, J., Xu, B., Li, Z., Li, X., Wu, X., & Liu, H. (2020) · Technology in Cancer Research & Treatment · doi:10.1177/1533033820971600 · Cited by 1
Retracted

Authors: Azzoli, C. G., Baker, S., Temin, S., Pao, W., Aliff, T., Brahmer, J., Johnson, D. H., Laskin, J. L., Masters, G., Milton, D., Nordquist, L., Pfister, D. G., Piantadosi, S., Schiller, J. H., Smith, R., Smith, T. J., Strawn, J. R., Trent, D., & Giaccone, G.
Affiliations: American Society of Clinical Oncology (US)
ORCID: Azzoli, Christopher G.
Temin, Sarah
Pao, William
Brahmer, Julie
Johnson, David H.
Masters, Gregory
Pfister, David G.
Piantadosi, Steven
Schiller, Joan H.
Smith, Thomas J.
Giaccone, Giuseppe
Venue: Journal of Clinical Oncology
Publisher: American Society of Clinical Oncology (ASCO)
Published: 2009-12-20
Volume: 27
Issue: 36
Pages: 6251-6266
ISSN: 0732-183X (ISSN-L)
1527-7755
DOI: 10.1200/jco.2009.23.5622
PMC: PMC2793036
OpenAlex: W2119366998
Cited by: 915
References: 218
Citations by year: 2026: 6 · 2025: 4 · 2024: 9 · 2023: 8 · 2022: 12 · 2021: 25 · 2020: 21 · 2019: 33 · 2018: 38 · 2017: 38 · 2016: 67 · 2015: 89 · 2014: 111 · 2013: 128 · 2012: 119
FWCI: 90.05
Type: journal article
Language: en
Open access: green
www.ncbi.nlm.nih.gov
Locations: Journal of Clinical Oncology (publishedVersion)
PubMed Central (publishedVersion)
PubMed (publishedVersion)
Topics: Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Diagnosis and Treatment
Health Sciences › Medicine › Oncology › Lung Cancer Research Studies
Keywords: stage IV non-small cell lung cancer, chemotherapy, first-line therapy, second-line therapy, third-line therapy, gefitinib, erlotinib, bevacizumab, carboplatin-paclitaxel, cetuximab, docetaxel, EGFR mutation, platinum-based doublets, overall survival, progression-free survival, treatment toxicity
MeSH terms: Carcinoma, Non-Small-Cell Lung, Humans, Lung Neoplasms, Neoplasm Staging

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

American Society of Clinical Oncology Clinical Practice Guideline Update on Chemotherapy for Stage IV Non–Small-Cell Lung Cancer

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks